exposing Parkinson's disease's voices and faces.

Published Date: 26 Apr 2023

One million Americans currently have Parkinson's disease, and another 90,000 are diagnosed with it each year. It is currently the second most prevalent neurodegenerative disease in the country. And it's moving up to No. 1. However, few people are familiar with Parkinson's.

Read Full News

Latest News

Duchenne Drug Gets Three-month FDA Extension After New Data Submission

Capricor Therapeutics said on Monday the U.S. Food and Drug Administration had extended the review period for ⁠its experimental cell therapy for Duchenne muscular dystrophy...

Antiamyloids’ Long-Term Cognitive Benefits Questioned

A reanalysis of lecanemab and donanemab trials suggests cognitive decline accelerates in open-label extensions, matching placebo rates, and challenging claims that cognitive benefits increase over time.

Aspherical Lenslets Slow Myopia Progression in Kids

A novel spectacle lens design featuring aspherical lenslets reduced myopia progression in children by more than 70% compared with standard single-vision lenses over 24 months.

Did Vaping THC 'Wax' for 5 Days Cause This Teen Girl's Seizure?

Evidence for the effect of THC on seizure threshold is conflicting, clinicians say

What New Research Shows About Prenatal Pesticide Exposure and Autism Traits

— Chlorpyrifos and other organophosphate insecticides had no association at low exposure levels

Young Girl Dies From Rare Brain-Eating Amoeba

Louisiana experienced its first confirmed Naegleria fowleri infection since 2013

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Latest News

Capricor Therapeutics said on Monday the U.S. Food and Drug Administration had extended the review period for ⁠its experimental cell therapy for Duchenne muscular dystrophy...

A reanalysis of lecanemab and donanemab trials suggests cognitive decline accelerates in open-label extensions, matching placebo rates, and challenging claims that cognitive benefits increase over time.

A novel spectacle lens design featuring aspherical lenslets reduced myopia progression in children by more than 70% compared with standard single-vision lenses over 24 months.

Evidence for the effect of THC on seizure threshold is conflicting, clinicians say

— Chlorpyrifos and other organophosphate insecticides had no association at low exposure levels

Louisiana experienced its first confirmed Naegleria fowleri infection since 2013

News All Time

Brain Worm Culprit in Woman's Hallucinations, Incoherent Speech

MRI uncovers neurocysticercosis in a 52-year-old woman

First-in-Class Drug for ADHD Wins FDA Approval

Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older

FDA Scientists Raise Questions About Duchenne Drug

Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data

Feds Delay Autism Meeting; Wildfire Smoke and Migraine; Mortality and MS

News and commentary from the world of neurology and neuroscience

Sugar Rationing in Early Life Linked to Lower Dementia Risk Decades Later

Long-term study looks at what happened when sugar was scarce

FDA Committee Votes Down Duchenne Drug

Agency staff and drug developer disagree on endpoints

Alzheimer's Paper Retracted; MS Before Epstein-Barr Infection; Brain Aging Map

News and commentary from the world of neurology and neuroscience

Fauci Successor Imminent; CDC Expands Outbreak List; Pesticides Linked to ALS

Health news and commentary gathered by MedPage Today staff

FDA Approves First-in-Class Narcolepsy Drug

Oveporexton treats more than symptoms, restores orexin signaling

Child Dies in Gene-Editing Trial; Wegovy & Dementia Score; RFK Jr. Questions Journal

News and commentary from the world of neurology and neuroscience

Trump Issues Controversial Order on Vaccines, Suggests Autism Link

Order calls for MMR vaccine to be split up, given at separate medical appointments

Pet Hamsters Linked to Rare Brain Disorder

Exposure was associated with autoimmune cerebellar ataxia in a hospital case-control study

CDC Warns of Severe Arboviral Disease With B-Cell Drugs

Cases have included chronic, neurodegenerative encephalitis that played out over months to years

Fact Focus: Trump's False Claims During Childhood Vaccine Order Signing

A closer look at the president's assertions

Trump's Vax Order Hands Some MAHA Voters a Win, but Gives Democrats an Attack Line

Voters can elect candidates who "stand for the science," said one physician running for Congress

CDC's Zombie Programs: Congress Funds Them, but Few People Are Left to Do the Work

Democrats say what's happening is illegal

Recommended News For You

Mindfulness-based interventions are advised by cancer organizations to treat patients' anxiety and depression.

The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

CAR-T cell therapy for cancer causes 'brain fog,' study shows

Recommended Articles For You

Obesity is a major risk factor for cancer 

Lymphomatoid Papulosis: What You Need to Know 

Immune Landscape Evolution in the Tumor Stromal Ecosystem 

Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues

2.

Brain cancer: a Q&A session.

3.

Women are more susceptible to the stress caused by inflation.

4.

Use of social media during pregnancy may increase depression.

5.

A new theranostic drug targets different cancer types.

1.

Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy

2.

How HLH is Revolutionizing Healthcare

3.

Unraveling the Mysteries of Burkitt Lymphoma: A New Hope for Treatment

4.

Landmark Medical Oncology Trials Redefining Early Breast Cancer Management

5.

Rehabilitation Through Prehabilitation Before Complex Cancer Surgery

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity

2.

Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations

3.

Should We Use DARA Up Front As First-Line Therapy in MM? - Part II

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

5.

From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot